Sign up
Pharma Capital

Biogen expands neurology portfolio, acquires Phase 2 asset for acute stroke in US$377mln

Japanese company TMS' drug TMS-007 is designed to break down blood clots and prevent inflammation
Blood clot
Strokes are the fifth-leading cause of death, according to the CDC

Biogen Inc (NASDAQ:BIIB) has entered into an options agreement with TMS Co Ltd’s Phase 2 asset for acute stroke.

Biogen will pay the Japanese pharma company a total of US$377mln, broken down to US$4mln upfront and US$18mln, once the option is exercised followed by US$355mln in milestone payments and royalties.

READ: Takeda Pharmaceutical Company formally closes acquisition of Belgian drug maker TiGenix

TMS’ drug TMS-007 is an acute stroke treatment designed to break down blood cost and prevent inflammation near the clot.

Strokes are the fifth leading cause of death and are responsible for one out of every 20 deaths, according to the CDC.

“By growing our acute neurology portfolio, we aim to make new advances in a disease that in the past decades has seen limited therapeutic innovation,” said Michael Ehlers, Biogen’s executive vice president of research and developments, in a press release.

Shares of the Massachusetts-based company were nearly 2% at US$303.75 by the closing bell Wednesday and were flat in Thursday pre-market trading.



Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.